Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
  • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D249/14—Nitrogen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/06—Anti-spasmodics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

• This invention relates to new triazolyl thioamide derivatives, a process for the preparation thereof, pharmaceutical compositions comprising the same, to the use of the said triazolyl thioamide derivatives for the treatment of diseases and for the preparation of pharmaceutical compositions suitable for the treatment of diseases.
• R 1 stands for straight or branched chained alkyl group comprising 1 to 6 carbon atom(s), or a group of the formula NR 2 R 3 , wherein
• R 2 and R 3 each represent hydrogen, straight or branched chained C 1-4 alkyl or C 2-6 alkenyl group
• Y denotes C 1-4 alkyl optionally bearing one or more hydroxyl or C 1-4 alkoxy substituent(s), phenyl-(C 1-4 alkyl) optionally bearing on the phenyl ring one or more C 1-4 alkoxy group(s), or phenoxy-(C 1-4 alkyl) optionally substituted on the phenyl ring by a C 1-4 alkyl bearing a heterocyclic group containing a nitrogen atom.
• the invention encompasses all the isomers or tautomeric forms of the compounds of general formula (I).
• the compounds according to the present invention posses tranquillant, antidepressant, spasmolytic, antiinflammatory, analgesic and antiperistaltic effects, furthermore they can be used as starting materials of other pharmaceutically active derivatives as well.
• heterocyclic group used throughout the specification relates to 4 to 8 membered heterocyclic groups which can be formed from compounds comprising independently one or more nitrogen and/or oxygen atom(s) or a group which can be obtained by condensing the same compounds with each other or with benzene.
• groups may be aromatic or partially or completely saturated. As examples for such groups e.g.
• piperidyl, morpholinyl, piperazinyl, furyl, imidazolyl, pyridyl, pyrimidinyl, pyrrolyl, pyrazolyl, pyridazinyl, isoxazolyl, pyrrolinyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, pyranyl or delta-3-piperidin-1-yl groups are mentioned.
• alkyl group relates to straight or branched chained saturated aliphatic hydrocarbon groups having 1 to 4 or 1 to 6 carbon atom(s), e.g. methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, tert.butyl, pentyl, hexyl etc.
• alkoxy group relates to alkyl ether groups comprising C 1-4 alkyl groups, e.g. methoxy, ethoxy, tert.butoxy etc.
• C 2-6 alkenyl groups straight or branched chained alkenyl groups are mentioned, e.g. vinyl, allyl, 2-methylallyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 2-pentenyl, 2-hexenyl, etc.
• Particularly preferred representatives of the compounds of the general formula (I) are the following derivatives: 1-[5-amino-3-(4-methylpiperazinyl)-1H-1,2,4-triazol-1-yl]-N- ⁇ 3-[3-(1-piperidinylmethyl)phenoxy]propyl ⁇ carbothioamide, 1-[5-amino-3-methylthio-1H-1,2,4-triazol-1-yl]-N-[2-(3,4-di-methoxyphenyl)ethyl]carbothioamide, 1-(5-amino-3-morpholino-1H-1,2,4-triazol-1-yl)-N- ⁇ 3-[3-(1-piperidinylmethyl)pnehoxy]propyl ⁇ carbothioamide, 1-[5-amino-3-dimethylamino-1H-1,2,4-triazol-1-yl]-N- ⁇ 3-[3-(1-piperidinylmethyl)
• the compounds of the general formula (I) are organic bases, so they can be transformed into acid addition salts.
• the pharmaceutically acceptable acid addition salts of the compounds of the general formula (I) can be formed with inorganic or organic acids.
• the hydrohalides such as hydrochlorides or hydrobromides
• carbonates, sulfates, acetates, fumarates, maleates, citrates, ascorbinates and tartarates can be mentioned.
• a process for the preparation of triazolyl thioamide derivatives of the general formula (I) and pharmaceutically acceptable acid addition salts thereof which comprises reacting a triazolyl dithioester of the general formula (II), ##STR3## wherein Q is as stated above and R 4 represents C 1-4 alkyl or phenyl-(C 1-4 alkyl) optionally substituted by a halogen atom, with an amine derivative of the general formula (III),
• the reaction is preferably performed in a solvent inert toward the reactants.
• a solvent inert toward the reactants preferably alcohols, (such as methanol, ethanol, propanol, i-propanol, n-butanol, i-butanol, tert.butanol), halogenated hydrocarbons (such as chloroform, dichloromethane, 1,2-dichloroethane, 1,1,2-trichloroethylene), dioxane or dimethyl sulfoxide can be used.
• the reaction is carried out at a temperature between 0° C. and 160° C., preferably between 20° C. and 120° C.
• the compounds of the general formula (I) obtained in form of a base can be converted into acid addition salts by methods known per se.
• the free base is reacted with the corresponding acid in an inert solvent.
• the triazolyl esters of the general formula (II) used as starting materials are known compounds or can be produced on the analogy of the known compounds (U.S. Pat. specification No. 3,686,301; DD patent specification No. 105,897).
• the amines of the general formula (III) are commercial products or can be produced as described in Houben-Weyl: Methoden der Organischen Chemie, Band XI/1, Georg Thieme Verlag, Stuttgart, 1957.
• the compounds according to the present invention exhibit excellent biological activity and low toxicity. They possess tranquillant and/or antidepressant and spasmolytic effects which are accompanied in some cases by antiinflammatory, analgesic and antiperistaltic properties.
• mice were treated perorally, with different doses of the compounds to be tested.
• the control group was treated only with the corresponding carrier.
• tetrabenazine [3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydrobenzo[a]-quinolizine-2-one] was administered intraperitoneally at a dosage of 50 mg/kg.
• the number of animals having closed palpebral fissure was determined in each group after 30, 60, 90 and 120 minutes, resp.
• the therapeutical index of the compound of the invention is several times higher than that of the amitryptiline widely used in the clinical practice with good results.
• mice consisting of 10 mice each were treated with 6 mg/kg of reserpine, subcutaneously, according to the method of Hoffmeister et. al. [Arzneim. Anlagen 19, 846-858 (1969)] After 60 minutes the compounds tested were administered to the animals, while the animals of the control group were treated with the corresponding vehicle without the active agent. The animals with ptosis were counted 60 and 120 minutes after the administration of the compounds to be tested. Evaluation was carried out as given under the above test. The results obtained are shown in Table II.
• the compounds of the general formula (I) are superior to the reference compound concerning both the absolute dose and the therapeutical index.
• mice The test was performed on white mice according to a modified method of Banziger and Hane [Arch. Int. Pharmacodyn. 167, 245 (1967)]. Each group of animals consisting of 6 mice was treated orally with the compound to be tested and the vehicle without active agent, respectively. One hour after the treatment a dosage of 125 mg/kg of pentetrazole was administered to each animal, intraperitoneally, and the tonic extensoric spasms of the hind limbs were recorded. The results are shown in Table III.
• test was carried out according to the method of Stone. [Arch. Int. Pharmacodyn. 117, 419 (1958)].
• the test compounds and the carrier, respectively, were administered orally; an hour later the animals received a 1.4 mg/kg i.v. dose of nicotine and the spasms and lethality were registered within an hour for the treated and control groups.
• Table IV The results are summarized in Table IV.
• the therapeutical wideness of the test compound exceeds that of the trihexyphenidyl used as reference substance.
• the test was carried out on white mice with the aid of Kaergaard's method [Arch. Int. Pharmacodyn. 2, 170 (1967)]. Groups consisting of six mice were used for each dose.
• the test compound was administered orally and one hour after this treatment narcosis was induced by means of a 40 mg/kg i.v. dose of hexobarbital.
• the control group received carrier instead of the test compound.
• mice were considered to have a positive reaction which show a narcosis time at least 2.5 times longer than that of the control group.
• the ED 50 values thus transformed were calculated. The results are summarized in Table V.
• compositions comprising as active ingredient at least one compound of the general formula (I) or a pharmaceutically acceptable acid addition salt thereof in admixture with suitable inert solid or liquid pharmaceutical carriers.
• compositions of the present invention can be prepared by methods known per se by admixing the active ingredient with suitable inert solid or liquid carriers and bringing the mixture to galenic form.
• compositions of the present invention may be suitable for oral (e.g. tablet, pill, coated pill, dragee, solid or soft gelatine capsule, solution, emulsion or suspension), parenteral (e.g. injection solution) or rectal (e.g. suppository) administration.
• oral e.g. tablet, pill, coated pill, dragee, solid or soft gelatine capsule, solution, emulsion or suspension
• parenteral e.g. injection solution
• rectal e.g. suppository
• coated tablets, dragees and solid gelatine capsules e.g. lactose, corn starch, potatoe starch, talc, magnesium carbonate, magnesium stearate, calcium carbonate, stearic acid or the salts thereof, etc.
• soft gelatine capsules e.g. vegetable oils, fats, waxes or polyols of suitable consistency can be used.
• solutions and syrups e.g. water, polyols (polyethylene glycol), saccharose or glucose can be used.
• the injection solutions can comprise e.g. water, alcohols, polyols, glycerol or vegetable oils as carrier.
• the suppositories can be prepared with the aid of e.g. oils, waxes, fats or polyols of suitable consistency.
• the pharmaceutical formulations may comprise auxiliaries usually applied in pharmaceutical industry, e.g. wetting, sweetening agents, aroma substances, salts causing the change of osmotic pressure, buffers, etc.
• the pharmaceutical formulations may further comprise other active ingredients, too.
• the compounds of the general formula (I) can preferably be used in therapy orally in the form of tablets or capsules. Especially preferred are the capsules or tablets comprising about 250 mg of active ingredient.
• the daily dose of the compounds of the general formula (I) can vary within wide ranges depending on several factors, e.g. on the activity of the active ingredient, the patient's condition and age, the severity of the disease, etc.
• the oral dose is generally 10 to 10,000 mg/day, preferably 50 to 1000 mg/day. It has to be stressed that these dose values are only of informative character and the administered dose must always be determined by the physician therapeutist.
• a method of tranquillant, anti-depressant and /or spasmolytic treatment which comprises administering to the patient an effective amount of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof.
• Tablets having the following composition are prepared by known methods of the pharmaceutical industry:
• Ointments having the following composition are prepared by known methods of the pharmaceutical industry:
• the active ingredient is in the outer phase of the ointment, in dissolved state.
• Suppositories having the following composition are prepared by known methods of the pharmaceutical industry:
• Capsules having the following composition are prepared by known methods of the pharmaceutical industry:

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Rheumatology (AREA)
• Anesthesiology (AREA)
• Urology & Nephrology (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Cephalosporin Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=10971287

Family Applications (2)

Family Applications After (1)

Country Status (22)

Families Citing this family (1)

Citations (3)

Family Cites Families (1)

• 1989
  • 1989-11-24 HU HU896163A patent/HU206096B/hu not_active IP Right Cessation
• 1990
  • 1990-11-21 PH PH41587A patent/PH27376A/en unknown
  • 1990-11-21 US US07/617,126 patent/US5175163A/en not_active Expired - Fee Related
  • 1990-11-22 BG BG093292A patent/BG60318B2/bg unknown
  • 1990-11-22 JP JP2315680A patent/JPH03209371A/ja active Pending
  • 1990-11-23 ZA ZA909409A patent/ZA909409B/xx unknown
  • 1990-11-23 FI FI905800A patent/FI905800A/fi not_active IP Right Cessation
  • 1990-11-23 EP EP90122351A patent/EP0434982B1/de not_active Expired - Lifetime
  • 1990-11-23 AT AT90122351T patent/ATE119888T1/de active
  • 1990-11-23 ES ES90122351T patent/ES2029778T3/es not_active Expired - Lifetime
  • 1990-11-23 KR KR1019900019076A patent/KR910009674A/ko not_active Application Discontinuation
  • 1990-11-23 IN IN950/MAS/90A patent/IN171500B/en unknown
  • 1990-11-23 PL PL90287909A patent/PL166887B1/pl unknown
  • 1990-11-23 CA CA002030775A patent/CA2030775A1/en not_active Abandoned
  • 1990-11-23 DK DK90122351.1T patent/DK0434982T3/da active
  • 1990-11-23 CZ CS905839A patent/CZ280559B6/cs unknown
  • 1990-11-23 RU SU904831825A patent/RU2045521C1/ru active
  • 1990-11-23 DE DE59008718T patent/DE59008718D1/de not_active Expired - Fee Related
  • 1990-11-23 IL IL96452A patent/IL96452A0/xx unknown
  • 1990-11-24 CN CN90109404A patent/CN1052116A/zh active Pending
• 1991
  • 1991-03-23 TW TW079109927A patent/TW210335B/zh active
  • 1991-09-09 US US07/755,219 patent/US5276030A/en not_active Expired - Fee Related
  • 1991-12-10 GR GR91300109T patent/GR910300109T1/el unknown

Patent Citations (3)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events